# Electronic Systems, Electronic Records, and Electronic Signatures in Clinical Investigations 

# Questions and Answers

# Guidance for Industry

# *DRAFT GUIDANCE*

```中文翻译
```

This guidance document is being distributed for comment purposes only.

## I. INTRODUCTION

This document provides guidance to sponsors, clinical investigators, institutional review boards
(IRBs), contract research organizations (CROs), and other interested parties on the use of electronic systems, electronic records, and electronic signatures in clinical investigations of
medical products, foods, tobacco products, and new animal drugs. The guidance provides
recommendations regarding the requirements, including the requirements under 21 CFR part 11
(part 11), under which FDA considers electronic systems, electronic records, and electronic signatures to be trustworthy, reliable, and generally equivalent to paper records and handwritten signatures executed on paper.

```中文翻译
I. 简介
这份文档为临床研究中医疗产品、食品、烟草制品和新型动物药的申办方，临床研究者，机构审查委员会(IRBs)，合同研究组织(CROs) 和其他使用电子化系统，电子记录，电子签名的相关方提供指导。
该指导提供关于要求的建议，其中要求的内容就包括 21 CFR part 11（part 11)，在此要求下 FDA 认为电子化系统，电子记录和电子签名是值得信赖的，可靠的，并且通常等同于纸质记录和手写签名。
```

This guidance revises the draft guidance for industry Use of Electronic Records and Electronic
Signatures in Clinical Investigations Under 21 CFR Part 11 — Questions and Answers (June
2017). This guidance expands upon recommendations in the guidance for industry Part 11,
Electronic Records; Electronic Signatures — Scope and Application (August 2003) (2003 part
11 guidance) that pertain to clinical investigations conducted under 21 CFR parts 312 and 812.
When finalized, this guidance will supersede the guidance for industry Computerized Systems
Used in Clinical Investigations (May 2007). Other related guidances are included in the
Appendix.

```中文翻译
本指南修订了2017年6月发布的《临床研究下基于21 CFR Part 11电子记录和电子签名的行业用途 -- 问题和回复》的指导意见草案。
```

